Increased serum remnant lipoproteins in patients with apolipoprotein E7 (apo ESuita)
Abstract
Apolipoprotein (apo) E7 was originally identified by Yamamura et al. in subjects with atherosclerotic cardiovascular diseases (J. Clin. Invest. 1984;74:1229). However, the lipoprotein abnormalities associated with apo E7 phenotype have not been elucidated. In the current study, to clarify the physiological roles of apo E7, lipoprotein abnormalities were studied in 12 apo E7 heterozygotes. A total of seven subjects were hyperlipidemic and five subjects were normolipidemic. The apo E phenotype was apo E7/3 in 11 subjects and apo E7/4 in one subject. Polymerase chain reaction revealed that all of the subjects with apo E7 phenotype had the same mutation as that of apo E(Suita) as reported previously (J. Biochem. 1989;105:249). All the hyperlipidemic subjects were over 40 years of age and two of them also had and severe coronary heart disease. Ultracentrifugal analysis revealed that the cholesterol level both in very low density lipoprotein and in intermediate density lipoprotein (IDL) was substantially higher in hyperlipidemic apo E7 heterozygotes, compared with control subjects and that the IDL cholesterol was also increased even in normolipidemic apo E7 heterozygotes. Polyacrylamide gel electrophoresis of lipoproteins showed a midband, which implies the increase of remnant lipoproteins, in 11 subjects out of 12, irrespective of the presence or absence of hyperlipoproteinemia. In two cases, a broad beta pattern was observed similar to that seen in type III hyperlipoproteinemia.…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
APOE2 Dunedin (Arg228Cys), APOE2 (Val236Glu), APOE7 Suita (Glu244,245Lys) (all heterozygotes), and APOE3 (Arg251 Gly, Cys112Arg) in the C-terminal domain were identified as variants that cause hypertriglyceridemia or CHL.
“APOE2 Dunedin (Arg228Cys)121), APOE2 (Val236Glu)122), APOE7 Suita (Glu244,245Lys)123, 14) (all heterozygotes), and APOE3 (Arg251 Gly, Cys112Arg) 122) in the C-terminal domain were identified as variants that cause hypertriglyceridemia or CHL.”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [123]
Cites
Human apolipoprotein E. The complete amino acid sequence
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34702-1 · Cited by 741 · see citing works
Abnormal in vivo metabolism of apolipoprotein E4 in humans.
Gregg, R. E., Zech, L. A., Schaefer, E. J., Stark, D., Wilson, D., & Brewer, H. B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112645 · Cited by 345 · see citing works
Rall, S. C., Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.15.4696 · Cited by 345 · see citing works
Wardell, M. R., Brennan, S. O., Janus, E. D., Fraser, R., & Carrell, R. W. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113096 · Cited by 159 · see citing works
de Knijff, P., van den Maagdenberg, A. M., Stalenhoef, A. F., Leuven, J. A., Demacker, P. N., Kuyt, L. P., Frants, R. R., & Havekes, L. M. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115349 · Cited by 100 · see citing works
Wardell, M. R., Weisgraber, K. H., Havekes, L. M., & Rall, S. C. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)30067-5 · Cited by 80 · see citing works
Analysis of Apolipoprotein E5 Gene from a Patient with Hyperlipoproteinemia1
Tajima, S., Yamamura, T., & Yamamoto, A. (1988) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a122420 · Cited by 42 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
APOE gene variants in primary dyslipidemia
Khalil, Y. A., Rabès, J.-P., Boileau, C., & Varret, M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.007 · Cited by 170 · see citing works
Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features
Matsunaga, A., & Saito, T. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65393 · Cited by 14 · see citing works
Hypertriglyceridemia and pancreatitis in a patient with apolipoprotein E7 (p.[E244K; E245K])/E4
Arai, M., Nishimura, A., Mori, Y., Ebara, T., & Okubo, M. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.06.001 · Cited by 2 · see citing works
- Authors
- Yanagi, K., Yamashita, S., Hiraoka, H., Ishigami, M., Kihara, S., Hirano, K.-I., Sakai, N., Nozaki, S., Funahashi, T., Kameda-Takemura, K., Kubo, M., Tokunaga, K., & Matsuzawa, Y.
- Affiliations
- Osaka University Hospital (JP)
- The University of Osaka (JP)
- Corresponding author
- Yamashita, Shizuya
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 1997-05
- Volume
- 131
- Issue
- 1
- Pages
- 49-58
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2115354652
- Cited by
- 16
- References
- 7
- Citations by year
- 2025: 1 · 2022: 2 · 2021: 2 · 2017: 1 · 2016: 1 · 2014: 2 · 2013: 1
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Atherosclerosis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (3557117, 4404085)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein E, remnant lipoproteins, hyperlipoproteinemia, intermediate-density lipoprotein cholesterol, VLDL cholesterol, type III hyperlipoproteinemia, dietary therapy, hyperlipidemia, coronary artery disease, obesity, aging, impaired glucose metabolism, lipoprotein metabolism
- MeSH terms
- Adult, Aged, Apolipoproteins E, Carrier Proteins, Cholesterol, DNA, Electrophoresis, Polyacrylamide Gel, Glycoproteins, Heterozygote, Humans, Hyperlipidemias, Lipoproteins, Middle Aged, Cholesterol, VLDL, Polymerase Chain Reaction, Apolipoprotein E3, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review